|
1
|
Pouyan A, Ghorbanlo M, Eslami M,
Jahanshahi M, Ziaei E, Salami A, Mokhtari K, Shahpasand K, Farahani
N, Meybodi TE, et al: Glioblastoma multiforme: Insights into
pathogenesis, key signaling pathways, and therapeutic strategies.
Mol Cancer. 24(58)2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ostrom QT, Patil N, Cioffi G, Waite K,
Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2013-2017. Neuro Oncol. 22 (12 Suppl
2):iv1–iv96. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang L, Liang B, Li YI, Liu X, Huang J and
Li YM: What is the advance of extent of resection in glioblastoma
surgical treatment-a systematic review. Chin Neurosurg J.
5(2)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Roh TH and Kim SH: Supramaximal resection
for glioblastoma: Redefining the extent of resection criteria and
its impact on survival. Brain Tumor Res Treat. 11:166–172.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kow CY, Kim BJH, Park TIH, Chen JCC, Vong
CK, Kim JY, Shim V, Dragunow M and Heppner P: Extent of resection
affects prognosis for patients with glioblastoma in non-eloquent
regions. J Clin Neurosci. 80:242–249. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stummer W, Reulen HJ, Meinel T, Pichlmeier
U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B,
Woiciechowsky C, et al: Extent of resection and survival in
glioblastoma multiforme: Identification of and adjustment for bias.
Neurosurgery. 62:564–576. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Stendel R: Extent of resection and
survival in glioblastoma multiforme: Identification of and
adjustment for bias. Neurosurgery. 64(E1206)2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Casas A: Clinical uses of
5-aminolaevulinic acid in photodynamic treatment and photodetection
of cancer: A review. Cancer Lett. 490:165–173. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Maragkos GA, Schüpper AJ, Lakomkin N,
Sideras P, Price G, Baron R, Hamilton T, Haider S, Lee IY,
Hadjipanayis CG and Robin AM: Fluorescence-guided high-grade glioma
surgery more than four hours after 5-aminolevulinic acid
administration. Front Neurol. 12(644804)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hadjipanayis CG and Stummer W: 5-ALA and
FDA approval for glioma surgery. J Neurooncol. 141:479–486.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Stummer W, Novotny A, Stepp H, Goetz C,
Bise K and Reulen HJ: Fluorescence-guided resection of glioblastoma
multiforme by using 5-aminolevulinic acid-induced porphyrins: A
prospective study in 52 consecutive patients. J Neurosurg.
93:1003–1013. 2000.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mazurek M, Szczepanek D, Orzyłowska A and
Rola R: Analysis of factors affecting 5-ALA fluorescence intensity
in visualizing glial tumor cells-literature review. Int J Mol Sci.
23(926)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Stummer W, Pichlmeier U, Meinel T,
Wiestler OD, Zanella F and Reulen HJ: ALA-Glioma Study Group.
Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: A randomised controlled multicentre
phase III trial. Lancet Oncol. 7:392–401. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stummer W, Tonn JC, Goetz C, Ullrich W,
Stepp H, Bink A, Pietsch T and Pichlmeier U: 5-Aminolevulinic
acid-derived tumor fluorescence: The diagnostic accuracy of visible
fluorescence qualities as corroborated by spectrometry and
histology and postoperative imaging. Neurosurgery. 74:310–320.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Roberts DW, Valdés PA, Harris BT, Fontaine
KM, Hartov A, Fan X, Ji S, Lollis SS, Pogue BW, Leblond F, et al:
Coregistered fluorescence-enhanced tumor resection of malignant
glioma: Relationships between δ-aminolevulinic acid-induced
protoporphyrin IX fluorescence, magnetic resonance imaging
enhancement, and neuropathological parameters. Clinical article. J
Neurosurg. 114:595–603. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lau D, Hervey-Jumper SL, Chang S, Molinaro
AM, McDermott MW, Phillips JJ and Berger MS: A prospective phase II
clinical trial of 5-aminolevulinic acid to assess the correlation
of intraoperative fluorescence intensity and degree of histologic
cellularity during resection of high-grade gliomas. J Neurosurg.
124:1300–1309. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Idoate MA, Díez Valle R, Echeveste J and
Tejada S: Pathological characterization of the glioblastoma border
as shown during surgery using 5-aminolevulinic acid-induced
fluorescence. Neuropathology. 31:575–582. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Omoto K, Matsuda R, Nakai Y, Tatsumi Y,
Nakazawa T, Tanaka Y, Shida Y, Murakami T, Nishimura F, Nakagawa I,
et al: Expression of peptide transporter 1 has a positive
correlation in protoporphyrin IX accumulation induced by
5-aminolevulinic acid with photodynamic detection of non-small cell
lung cancer and metastatic brain tumor specimens originating from
non-small cell lung cancer. Photodiagnosis Photodyn Ther.
25:309–316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hagiya Y, Fukuhara H, Matsumoto K, Endo Y,
Nakajima M, Tanaka T, Okura I, Kurabayashi A, Furihata M, Inoue K
and Ogura SI: Expression levels of PEPT1 and ABCG2 play key roles
in 5-aminolevulinic acid (ALA)-induced tumor-specific
protoporphyrin IX (PpIX) accumulation in bladder cancer.
Photodiagnosis Photodyn Ther. 10:288–295. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hou C, Yamaguchi S, Ishi Y, Terasaka S,
Kobayashi H, Motegi H, Hatanaka KC and Houkin K: Identification of
PEPT2 as an important candidate molecule in 5-ALA-mediated
fluorescence-guided surgery in WHO grade II/III gliomas. J
Neurooncol. 143:197–206. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Morita M, Tanaka H, Kumamoto Y, Nakamura
A, Harada Y, Ogata T, Sakaguchi K, Taguchi T and Takamatsu T:
Fluorescence-based discrimination of breast cancer cells by direct
exposure to 5-aminolevulinic acid. Cancer Med. 8:5524–5533.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang W, Tabu K, Hagiya Y, Sugiyama Y,
Kokubu Y, Murota Y, Ogura SI and Taga T: Enhancement of
5-aminolevulinic acid-based fluorescence detection of side
population-defined glioma stem cells by iron chelation. Sci Rep.
7(42070)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
D'Amico AG, Maugeri G, Vanella L, Consoli
V, Sorrenti V, Bruno F, Federico C, Fallica AN, Pittalà V and
D'Agata V: Novel acetamide-based HO-1 inhibitor counteracts
glioblastoma progression by interfering with the hypoxic-angiogenic
pathway. Int J Mol Sci. 25(5389)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Virtuoso A, D'Amico G, Scalia F, De Luca
C, Papa M, Maugeri G, D'Agata V, Caruso Bavisotto C and D'Amico AG:
The interplay between glioblastoma cells and tumor
microenvironment: New perspectives for early diagnosis and targeted
cancer therapy. Brain Sci. 14(331)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
D'Amico AG, Caruso Bavisotto C and
Virtuoso A: Identifi-cation of molecular targets and anti-cancer
agents in GBM: New perspectives for cancer therapy. Brain Sci.
13(1078)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
D'Amico AG, Maugeri G, Magrì B, Giunta S,
Saccone S, Federico C, Pricoco E, Broggi G, Caltabiano R, Musumeci
G, et al: Modulatory activity of ADNP on the hypoxia-induced
angiogenic process in glioblastoma. Int J Oncol.
62(14)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ihata T, Nonoguchi N, Fujishiro T, Omura
N, Kawabata S, Kajimoto Y and Wanibuchi M: The effect of hypoxia on
photodynamic therapy with 5-aminolevulinic acid in malignant
gliomas. Photodiagnosis Photodyn Ther. 40(103056)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Maugeri G, D'Amico AG, Saccone S, Federico
C, Rasà DM, Caltabiano R, Broggi G, Giunta S, Musumeci G and
D'Agata V: Effect of PACAP on hypoxia-induced angiogenesis and
epithelial-mesenchymal transition in glioblastoma. Biomedicines.
9(965)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kostron H: Photodynamic diagnosis and
therapy and the brain. Methods Mol Biol. 635:261–280.
2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Park J, Oh SJ, Shim JK, Ji YB, Moon JH,
Kim EH, Huh YM, Suh JS, Chang JH, Lee SJ and Kang SG: C5α secreted
by tumor mesenchymal stem-like cells mediates resistance to
5-aminolevulinic acid-based photodynamic therapy against
glioblastoma tumorspheres. J Cancer Res Clin Oncol. 149:4391–4402.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Korotkevich G, Sukhov V, Budin N, Shpak B,
Artyomov MN and Sergushichev A: Fast gene set enrichment analysis.
bioRxiv: 060012, 2021.
|
|
33
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bowman RL, Wang Q, Carro A, Verhaak RG and
Squatrito M: GlioVis data portal for visualization and analysis of
brain tumor expression datasets. Neuro Oncol. 19:139–141.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Giachino C, Boulay JL, Ivanek R, Alvarado
A, Tostado C, Lugert S, Tchorz J, Coban M, Mariani L, Bettler B, et
al: A tumor suppressor function for notch signaling in forebrain
tumor subtypes. Cancer Cell. 28:730–742. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chung S and Kim C: Comparative analysis of
transcription factors TWIST2, GATA3, and HES5 in glioblastoma
multiforme: Evaluating biomarker potential and therapeutic targets
using in silico methods. J Korean Neurosurg Soc. 68:202–212.
2025.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang M, Jia J, Cui Y, Peng Y and Jiang Y:
CD73-positive extracellular vesicles promote glioblastoma
immunosuppression by inhibiting T-cell clonal expansion. Cell Death
Dis. 12(1065)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Przygodzka P, Soboska K, Sochacka E and
Boncela J: Erratum: Neuromedin U: A small peptide in the big world
of cancer. Cancers 2019, 11, 1312. Cancers (Basel).
12(251)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wu Y, Li F, Yang C, Zhang X, Xue Z, Sun Y,
Lin X, Liu X, Zhao Z, Huang B, et al: Super-enhancer-driven
SLCO4A1-AS1 is a new biomarker and a promising therapeutic target
in glioblastoma. Sci Rep. 15(954)2025.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Qi M, Sun LA, Zheng LR, Zhang J, Han YL,
Wu F, Zhao J, Niu WH, Fei MX, Jiang XC and Zhou ML: Expression and
potential role of FOSB in glioma. Front Mol Neurosci.
15(972615)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Xiao M, Xue J and Jin E: SPOCK: Master
regulator of malignant tumors (review). Mol Med Rep.
30(231)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Mao H, Zhao X and Sun SC: NF-κB in
inflammation and cancer. Cell Mol Immunol. 22:811–839.
2025.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ceccarelli M, Barthel FP, Malta TM,
Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh
A, Pagnotta SM, et al: Molecular profiling reveals biologically
discrete subsets and pathways of progression in diffuse glioma.
Cell. 164:550–563. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Widhalm G, Olson J, Weller J, Bravo J, Han
SJ, Phillips J, Hervey-Jumper SL, Chang SM, Roberts DW and Berger
MS: The value of visible 5-ALA fluorescence and quantitative
protoporphyrin IX analysis for improved surgery of suspected
low-grade gliomas. J Neurosurg. 133:79–88. 2019.PubMed/NCBI View Article : Google Scholar
|
